Partner with Kaléo

Kaléo’s Aerio™ Auto-Injector Platform ensures the medical breakthroughs of our pharmaceutical and government agency partners are paired with custom-designed drug-delivery devices built to trust.

Engineering for a Healthier, Safer Future Together

The Aerio™ Auto-Injector Platform has broad application with the ability to successfully deliver complex therapeutic formulations. Our devices enable larger volume and higher viscosity formulations with controlled injection flow rates, making it versatile for a range of drugs and medical scenarios.

We take great pride in our partnerships with like-minded organizations seeking to improve the patient experience and save lives.

Scale for Success and Security

More than 12 million devices manufactured meeting the needs of patients globally.
First to achieve the U.S. Food and Drug Administration (FDA) draft guidance standard for 99.999% device reliability.
Robust manufacturing capabilities for an expansive range of formulations.
Fully automated robotic production line to deliver consistent quality.

Patient Focused

Designed to be easy-to-use, convenient, and portable to suit any lifestyle

Innovative Design

Leverages Human Factors Engineering for manufacturing excellence

Unmatched Capabilities

Combines ability to inject higher viscosity drugs and higher drug volumes

Market Leader

Leader in gas-powered auto injectors with over 12 million manufactured

Multiple Versions

Single syringe, cartridge, dual syringe, and dual chamber to suit various applications

Medical Countermeasures

Aerio for the Frontlines

Military personnel, first responders, and civilians are confronting unprecedented dangers from weaponized opioids, nerve agents, and other chemical hazards. By providing essential solutions in this space, Kaléo is proudly supporting and protecting the warfighter by bridging gaps in emergency response capabilities.

Kaléo’s advanced auto-injector platform is well-suited for modern medical countermeasures (MCM). With extensive experience in developing and delivering emergency-use devices, the Aerio platform stands out as uniquely suited for these challenges. It is designed to handle complex formulations and function in extreme conditions, making it versatile and built to trust in diverse emergency scenarios.

Protecting Military, Police, and Emergency Responders

At Kaléo, we recognize the impact that our drug-device combinations can offer to those who are on the frontlines, putting themselves at risk to protect others. We are committed to partnering with private organizations and government agencies to develop new drug-device combinations that enhance global health security.

Medical Countermeasures in Development

Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical)

RAD-A will be the first of a new generation of medical countermeasures utilizing an innovative reconstitution technology and is expected to significantly extend the shelf life of the drug as well as its stability under extreme conditions.

Center for the Biomedical Advanced Research and Development Authority (BARDA)

Novel pralidoxime chloride (2-PAM) auto-injector for organophosphate or nerve agent poisoning is part of the CHEMPACK program to provide communities with effective medical countermeasures.

Medical Countermeasures in Use

Request a Meeting

Request a meeting or view a demonstration video.

Partnership Opportunities

Partnerships